IKT · Inhibikase Therapeutics, Inc.
$2.35
-0.10 (-4.08%)
At close · Aug 20
Market Cap
$341.86M
Shares
139.54M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.35
Open$2.45
Day$2.33–2.47
52W close$1.41–2.47
Avg vol 30d817K
Short int19.1M · 13.7% float · 21.5d
Short vol26%
Last earningsAug 11, 2026
DataJun 2023–Aug 2026
Filing10-Q · Aug 11
Raw chart and full-history price indicators begin at the captured split on Jun 30, 2023; bars on opposite sides are not compared.
Up next
Next earnings call
Nov 11, 2026
Est · unconfirmed
· in 12 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+29%
above
Price vs 50-day avg
+11%
above
RSI (14)
54
neutral
MACD trend
Negative
52-week position
89%
near high
Momentum
relative strength
1-month return
+1%
trailing
6-month return
+15%
trailing
YTD return
+15%
this year
Relative strength
+3%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.71% of float · ▲ +4.8% MoM · 21.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
105 holders — near 3-yr high, broad support
Squeeze score
87
high risk · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
EPS growth
+58%
Y/Y
Free cash flow
$-27.8M
Balance sheet
$178.4M
net cash
Quant / Vol
risk profile
Volatility
65%
annualized · 1-yr
Max drawdown
−27%
past year
ATR
5.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+29%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
54
Neutral
MACD trend
Negative
Bearish
52-week position
89%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+1% holders QoQ · +19 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
13.71% of float · ▲ +4.8% MoM · 21.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
105 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $2 · 89%
Range high $2
vs 200-day avg +29%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IKT
this stock
Inhibikase Therapeutics, Inc.
|
$341.86M | +14.6% | -100.0% | — | 13.7% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
MRNA
Moderna, Inc.
|
$69.62B | +352.1% | +4.3% | — | 12.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jun 30, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IKT | -2.5% | +0.9% | +14.6% | +7.8% | +14.6% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | -0.5% | -2.5% | +3.5% | +5.7% | +2.8% |
Key facts
CIK
1750149
CUSIP
45719W205
13F (30d)
106 filings
104 filers
Visit website
Investor relations